These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25512369)

  • 1. Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways.
    Baker JE; Su J; Koprowski S; Dhanasekaran A; Aufderheide TP; Gross GJ
    J Pharmacol Exp Ther; 2015 Mar; 352(3):429-37. PubMed ID: 25512369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
    Erhardt JA; Erickson-Miller CL; Aivado M; Abboud M; Pillarisetti K; Toomey JR
    Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
    Matsuki E; Miyakawa Y; Yamane A; Okamoto S
    Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
    Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
    Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag--an oral thrombopoietin agonist.
    Sharma V; Randhawa H; Sharma A; Aggarwal S
    Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
    Xie CY; Xu YP; Zhao HB; Lou LG
    Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T; Imbach P
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
    Jeong JY; Levine MS; Abayasekara N; Berliner N; Laubach J; Vanasse GJ
    J Hematol Oncol; 2015 Apr; 8():37. PubMed ID: 25886818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
    Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
    Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy.
    Zuo S; Sun L; Wang Y; Chen B; Wang J; Ge X; Lu Y; Yang N; Shen P
    Cell Death Dis; 2021 Feb; 12(2):208. PubMed ID: 33627636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y; Kolesar JM
    Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent.
    Ko HT; Hsu LH; Yang SY; Chen YL
    Med Mycol; 2020 Jun; 58(4):493-504. PubMed ID: 31297540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eltrombopag promotes DNA repair in human hematopoietic stem and progenitor cells.
    Guenther KL; Cheruku PS; Cash A; Smith RH; Alvarado LJ; Burkett S; Townsley DM; Winkler T; Larochelle A
    Exp Hematol; 2019 May; 73():1-6.e6. PubMed ID: 30986494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ.
    Alvarado LJ; Huntsman HD; Cheng H; Townsley DM; Winkler T; Feng X; Dunbar CE; Young NS; Larochelle A
    Blood; 2019 May; 133(19):2043-2055. PubMed ID: 30803992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
    Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
    Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPL mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491.
    Levy G; Carillo S; Papoular B; Cassinat B; Zini JM; Leroy E; Varghese LN; Chachoua I; Defour JP; Smith SO; Constantinescu SN
    Blood; 2020 Mar; 135(12):948-953. PubMed ID: 31978223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes.
    Karliner JS; Honbo N; Summers K; Gray MO; Goetzl EJ
    J Mol Cell Cardiol; 2001 Sep; 33(9):1713-7. PubMed ID: 11549349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag inhibition of acute myeloid leukemia cell survival does not depend on c-Mpl expression.
    Sugita M; Kalota A; Gewirtz AM; Carroll M
    Leukemia; 2013 Apr; 27(5):1207-10. PubMed ID: 23183425
    [No Abstract]   [Full Text] [Related]  

  • 20. Hetrombopag, a Thrombopoietin Receptor Agonist, Protects Cardiomyocyte Survival from Oxidative Stress Damage as an Enhancer of Stem Cells.
    Zhou N; Wang J; Li X; Zhao Y; Sun Y; Zou C
    Cardiovasc Drugs Ther; 2016 Dec; 30(6):567-577. PubMed ID: 27838864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.